{"title":"Clinical Course After Radical Local Therapy for Oligo-Recurrence of Nonsmall Cell Lung Cancer.","authors":"Dai Sonoda, Raito Maruyama, Yasuto Kondo, Shunsuke Mitsuhashi, Satoru Tamagawa, Masahito Naito, Masashi Mikubo, Kazu Shiomi, Yukitoshi Satoh","doi":"10.1002/jso.28032","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Radical local therapy is effective for oligo-recurrence of non-small cell lung cancer (NSCLC). We retrospectively assessed patients with oligo-recurrent NSCLC and detailed the clinical course after radical local therapy.</p><p><strong>Methods: </strong>We analyzed 1028 patients who underwent complete resection for NSCLC. We defined oligo-recurrence as up to two metachronous recurrences, radical local therapy as local therapy performed with curative intent, and progressive disease as the appearance of new lesions/re-enlargement of the initial recurrence sites.</p><p><strong>Results: </strong>Of the 132 patients who developed oligo-recurrence, 88 received radical local therapy. Fifty-eight patients had progressive disease. Fifteen patients remained cancer free for > 5 years. Epidermal growth factor receptor (EGFR) positivity was associated with disease progression (odds ratio, 3.90; p = 0.025). Active treatment for disease progression (hazard ratio, 2.54; p = 0.012) and the absence of re-enlarged lesions at sites of radical local therapy for recurrence (hazard ratio, 2.32; p = 0.031) were associated with prolonged post-recurrence overall survival.</p><p><strong>Conclusions: </strong>Patients with EGFR mutations who develop oligo-recurrence should be monitored for disease progression. Re-enlargement of lesions after radical local therapy was associated with a poor prognosis. A good prognosis can be expected with active treatment, even in the event of disease progression.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.28032","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Radical local therapy is effective for oligo-recurrence of non-small cell lung cancer (NSCLC). We retrospectively assessed patients with oligo-recurrent NSCLC and detailed the clinical course after radical local therapy.
Methods: We analyzed 1028 patients who underwent complete resection for NSCLC. We defined oligo-recurrence as up to two metachronous recurrences, radical local therapy as local therapy performed with curative intent, and progressive disease as the appearance of new lesions/re-enlargement of the initial recurrence sites.
Results: Of the 132 patients who developed oligo-recurrence, 88 received radical local therapy. Fifty-eight patients had progressive disease. Fifteen patients remained cancer free for > 5 years. Epidermal growth factor receptor (EGFR) positivity was associated with disease progression (odds ratio, 3.90; p = 0.025). Active treatment for disease progression (hazard ratio, 2.54; p = 0.012) and the absence of re-enlarged lesions at sites of radical local therapy for recurrence (hazard ratio, 2.32; p = 0.031) were associated with prolonged post-recurrence overall survival.
Conclusions: Patients with EGFR mutations who develop oligo-recurrence should be monitored for disease progression. Re-enlargement of lesions after radical local therapy was associated with a poor prognosis. A good prognosis can be expected with active treatment, even in the event of disease progression.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.